A Phase 2 interventional study of EC-18 and Placebo EC-18 in COVID-19, sponsored by Enzychem Lifesciences Corporation. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2022-02-10.
Sponsored by Enzychem Lifesciences Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 90 studies in COVID-19 with a site in Korea, Republic of — 11 open to participants now, 19 under way, 6 of them phase 3. COVID-19 · Korea, Republic of.
Among the 90 studies in COVID-19 with a site in Korea, Republic of, this one is the 50th largest by enrollment of the 72 interventional ones that give a count, is one of 29 that started in 2020, is one of 17 in phase 2, and was the 16th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →11 of the 90 studies in COVID-19 with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Pfizer · Sites in Korea, Republic of, United States, Argentina and 15 more countries
Ages 18+
Pfizer · Sites in Korea, Republic of, United States, Argentina and 16 more countries
Ages 12+
Merck Sharp & Dohme LLC · Sites in Korea, Republic of, United States, Argentina and 21 more countries
Ages 18+
Jaehoon Ko · Sites in Korea, Republic of
Ages 19+
Pfizer · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
90 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 31 · Phase 3 30 · Phase 4 2
First in 2018; this study’s year is marked. 29 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 63 is below the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 253 across the 72 interventional studies, 730 across the 18 observational. Of the 58 that completed or were terminated, 21 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 90 have an industry lead sponsor. The 10 most frequent:
Enzychem Lifesciences Corporation is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Enzychem Lifesciences Corporation has 2 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
7 of the studies in COVID-19 with a site in Korea, Republic of that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT06613984PfizerKorean Post Marketing Surveillance for Comirnaty Injection (Bretovameran) | 2026-12-30 |
| NCT05032976PfizerKorea Comirnaty Post-marketing Surveillance | 2027-01-24 |
Add all 7 to your calendar (.ics) → With an account.
Among the 90 studies in COVID-19 with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Prevention of COVID-19 infection to severe pneumonea or ARDS
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
EC-18 QD
Drug: EC-18
Placebo EC-18 QD
Drug: Placebo EC-18
EC-18 QD
Placebo EC-18 QD
Rate of transition to ARDS
Time frame: 14 days after starting IP administration
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2020 to primary completion in Feb 2021, 8 months.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 8 months is close to that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mosedipimod
Enzychem Lifesciences Corporation